EPS for Zealand Pharma A/S (ZEAL) Expected At $-0.39; Renaissance Technologies Cut Its Nanostring Technologies (NSTG) Position

April 22, 2018 - By Winifred Garcia

NanoString Technologies, Inc. (NASDAQ:NSTG) Logo

Renaissance Technologies Llc decreased Nanostring Technologies Inc (NSTG) stake by 30.57% reported in 2017Q4 SEC filing. Renaissance Technologies Llc sold 85,100 shares as Nanostring Technologies Inc (NSTG)’s stock declined 11.72%. The Renaissance Technologies Llc holds 193,300 shares with $1.44M value, down from 278,400 last quarter. Nanostring Technologies Inc now has $236.09M valuation. The stock decreased 2.83% or $0.27 during the last trading session, reaching $9.28. About 59,820 shares traded. NanoString Technologies, Inc. (NASDAQ:NSTG) has declined 64.95% since April 22, 2017 and is downtrending. It has underperformed by 76.50% the S&P500.

Analysts expect Zealand Pharma A/S (NASDAQ:ZEAL) to report $-0.39 EPS on May, 16.After having $-0.58 EPS previously, Zealand Pharma A/S’s analysts see -32.76% EPS growth. The stock decreased 5.28% or $0.83 during the last trading session, reaching $14.9. About 7,248 shares traded. Zealand Pharma A/S (NASDAQ:ZEAL) has 0.00% since April 22, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await NanoString Technologies, Inc. (NASDAQ:NSTG) to report earnings on May, 8 after the close. They expect $-0.76 earnings per share, up 12.64% or $0.11 from last year’s $-0.87 per share. After $-0.34 actual earnings per share reported by NanoString Technologies, Inc. for the previous quarter, Wall Street now forecasts 123.53% negative EPS growth.

Renaissance Technologies Llc increased Osisko Gold Royalties Ltd (OKSKF) stake by 233,782 shares to 455,356 valued at $5.26M in 2017Q4. It also upped Rayonier Advanced Matls Inc (NYSE:RYAM) stake by 270,238 shares and now owns 3.98 million shares. International Speedway Corp (NASDAQ:ISCA) was raised too.

Since March 13, 2018, it had 1 buy, and 0 selling transactions for $207,300 activity. The insider YOUNG WILLIAM bought $207,300.

Investors sentiment decreased to 0.93 in 2017 Q4. Its down 0.97, from 1.9 in 2017Q3. It turned negative, as 22 investors sold NSTG shares while 21 reduced holdings. 15 funds opened positions while 25 raised stakes. 21.04 million shares or 3.61% less from 21.83 million shares in 2017Q3 were reported. Millennium Mgmt Limited Liability Company reported 0.01% stake. Tekla Cap Mngmt Lc invested in 74,250 shares. Prelude Mgmt Limited Liability reported 1,163 shares. Art Advisors Limited Company stated it has 0.01% in NanoString Technologies, Inc. (NASDAQ:NSTG). Parametric Portfolio Assoc Ltd Liability Co reported 12,065 shares. Northern has invested 0% of its portfolio in NanoString Technologies, Inc. (NASDAQ:NSTG). Jacobs Levy Equity Management, New Jersey-based fund reported 47,304 shares. Citigroup has invested 0% in NanoString Technologies, Inc. (NASDAQ:NSTG). Bancshares Of America Corporation De has invested 0% in NanoString Technologies, Inc. (NASDAQ:NSTG). Legal And General Public Ltd Com holds 0% or 5,799 shares. Cornerstone Cap Holdings Ltd Liability holds 0% or 8,200 shares in its portfolio. Platinum Investment accumulated 121,000 shares. Parallax Volatility Advisers LP owns 3,108 shares. 223,668 are held by Penn Cap Mgmt Company Inc. Walleye Trading Ltd Liability Corp has invested 0% in NanoString Technologies, Inc. (NASDAQ:NSTG).

Among 4 analysts covering NanoString Technologies (NASDAQ:NSTG), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. NanoString Technologies had 14 analyst reports since August 5, 2015 according to SRatingsIntel. As per Wednesday, December 20, the company rating was maintained by Cowen & Co. Zacks upgraded it to “Hold” rating and $16 target in Wednesday, August 12 report. The stock of NanoString Technologies, Inc. (NASDAQ:NSTG) earned “Buy” rating by Cowen & Co on Wednesday, September 27. The firm earned “Buy” rating on Monday, October 23 by Robert W. Baird. The rating was maintained by Cowen & Co on Monday, August 14 with “Buy”. Robert W. Baird maintained it with “Outperform” rating and $19 target in Thursday, October 12 report. As per Thursday, October 12, the company rating was downgraded by Janney Capital. The firm has “Outperform” rating by Robert W. Baird given on Friday, November 3. The company was maintained on Wednesday, August 5 by Leerink Swann. The company was maintained on Thursday, March 8 by Morgan Stanley.

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide medicines in Denmark. The company has market cap of $457.45 million. The firm markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. It currently has negative earnings. The Company’s products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes.

NanoString Technologies, Inc. (NASDAQ:NSTG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.